and they work by taking out amyloid beta from the brain. Amyloid is part of what causes Alzheimer's disease. Now, what we're ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the ...

With our clinical program gaining momentum and sabirnetug’s unique selectivity for toxic amyloid beta oligomers, we are excited about the potential to offer a next-generation treatment for early ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

A recent paper published in Nature Medicine sheds light on a remarkable case where Alzheimer's appears to have been medically acquired through the transmission of the amyloid-beta protein. Typically ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...